Global biopharmaceutical giant AbbVie has recently revealed that it has initiated substantive negotiations with multiple U.S. states, aiming to expand its domestic manufacturing capacity layout.

According to reports, this strategic consultation involves the construction of new production facilities and the upgrading of existing bases, with a new round of specific investment plans expected to be announced in 2026. These interstate negotiations highlight AbbVie's long-term strategy to strengthen supply chain resilience. By diversifying its production capacity layout, the company can both address geopolitical risks and optimize operational efficiency by leveraging differentiated industrial policies across states. Notably, the 2026 investment window coincides with several key patent expiration milestones, which may pave the way for the early commercialization of the next generation of blockbuster products. Industry observers point out that local investment decisions by biopharmaceutical companies are often accompanied by supporting policies such as tax incentives and talent recruitment. AbbVie's multi-pronged approach not only reflects its continued commitment to the U.S. domestic innovation ecosystem but also aligns with the Biden administration's Inflation Reduction Act, which incentivizes the reshoring of pharmaceutical manufacturing. As negotiations deepen, the specific scale of investment and job creation effects will become key variables for states competing for these projects.